Literature DB >> 15083991

Achieving remission in major depressive disorder: the first step to long-term recovery.

Jeffrey E Kelsey1.   

Abstract

Major Depressive Disorder (MDD) is a common clinical condition encountered in primary care practices. Left untreated or, more commonly, undertreated, MDD typically results in significant distress and dysfunction. Successful treatment of MDD, usually defined as achieving sustained remission, is an attainable goal. As such, sustained remission should be the goal sought by physicians and patients. A number of variables have an impact on the likelihood of achieving and sustaining remission including the length of the depressive episode, the completeness of the response to treatment, and whether remission is achieved relatively early in treatment. The selection of pharmacotherapeutic agents and the relative probability of achieving remission has only recently been investigated in outpatient populations, though this issue has been explored in inpatient studies for more than a decade. This article reviews these variables and presents strategies with the goal of achieving remission for patients with MDD. The importance of both pharmacotherapy, where indicated, as well as psychotherapy is discussed. Finally, remission is presented as a necessary first step to ensure an optimal long-term outcome, rather than as the final goal of treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15083991

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  6 in total

Review 1.  Amygdala real-time functional magnetic resonance imaging neurofeedback for major depressive disorder: A review.

Authors:  Kymberly D Young; Vadim Zotev; Raquel Phillips; Masaya Misaki; Wayne C Drevets; Jerzy Bodurka
Journal:  Psychiatry Clin Neurosci       Date:  2018-05-21       Impact factor: 5.188

2.  Creating an index to measure health state of depressed patients in automated healthcare databases: the methodology.

Authors:  Clément François; Adrian Tanasescu; François-Xavier Lamy; Nicolas Despiegel; Bruno Falissard; Ylana Chalem; Christophe Lançon; Pierre-Michel Llorca; Delphine Saragoussi; Patrice Verpillat; Alan G Wade; Djamel A Zighed
Journal:  J Mark Access Health Policy       Date:  2017-09-13

3.  Results and validation of an index to measure health state of patients with depression in automated healthcare databases.

Authors:  François-Xavier Lamy; Bruno Falissard; Clément François; Christophe Lançon; Pierre Michel Llorca; Adrian Tanasescu; Maëlys Touya; Patrice Verpillat; Alan G Wade; Delphine Saragoussi
Journal:  J Mark Access Health Policy       Date:  2019-01-22

4.  Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder.

Authors:  Kymberly D Young; Vadim Zotev; Raquel Phillips; Masaya Misaki; Han Yuan; Wayne C Drevets; Jerzy Bodurka
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

5.  Self-Reported Adverse Drug Reactions, Medication Adherence, and Clinical Outcomes among Major Depressive Disorder Patients in Ethiopia: A Prospective Hospital Based Study.

Authors:  Tadesse Melaku Abegaz; Lamessa Melese Sori; Hussien Nurahmed Toleha
Journal:  Psychiatry J       Date:  2017-11-14

6.  Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases.

Authors:  Maëlys Touya; François-Xavier Lamy; Adrian Tanasescu; Delphine Saragoussi; Clément François; Alan G Wade; Pierre-Michel Llorca; Christophe Lançon; Bruno Falissard
Journal:  J Mark Access Health Policy       Date:  2019-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.